Gilead's GS-5806 meets in RSV challenge study

Gilead Sciences Inc. (NASDAQ:GILD) said oral GS-5806 for five days met the primary endpoint of reducing respiratory syncytial virus (RSV) load from baseline to day 12 vs. placebo in a Phase IIa trial to treat RSV infection. GS-5806 also met secondary endpoints of improving mucus weight and symptom scores vs. placebo. Data -- which came from healthy volunteers who were infected with RSV intranasally -- were presented at the American Thoracic Society meeting in San Diego.

Gilead said it plans to start Phase II trials this year to treat RSV infection in naturally infected adults and adults who have undergone bone marrow transplantation. GS-5806 is an oral RSV fusion inhibitor. ...